MedSciNet has designed and launched the web-based application and database for CIT-09, a multi-center, prospective, non-randomized, observational study assessing the use of positron emission tomography (PET) CT imaging to quantify the beta cell mass (BCM) in subjects who have received an islet transplant.
Emerging opportunities for replacement therapies (islet transplantation and future transplantations of beta cells generated from stem cells) as potential treatment for T1D non-invasive monitoring of the transplanted beta cells will be critical to optimize cell survival, engraftment and post-transplantation management. While a range of potential markers have been investigated using various imaging technologies no effective probe has so far been developed that can be used to image BCM in humans.
Promising animal transplantation studies injecting a clinically available tracer 11C-5-HTP show the graft in the liver at repeated examinations. The 11C-5-HTP uptake correlates to the beta cell mass and does not correlate to the actual B-glucose.
The CIT-09 study aims to describe the relationship between beta cell mass measured by 11C-5-HTP PET CT and 90 minute stimulated c-peptide from the mixed meal tolerance test. In addition, the study will investigate the distributions of functioning islets in specified regions of the liver and their associations with fat accumulations in the liver.
CIT-09 is financed by NIH and will be performed by the Nordic Network for Clinical Islet Transplantation.